Generic Name and Formulations:
Yellow fever vaccine live; for SC inj; contains sorbitol, gelatin; preservative-free;.
Sanofi Pasteur, Inc.
Indications for YF-VAX:
Yellow fever immunization.
Adults and Children:
Give at least 10 days before expected exposure; may repeat every 10yrs. <9 months: not recommended. ≥9 months: 0.5mL SC.
Infants <9 months of age. Severe egg allergy (consider skin test and desensitization; see literature). Immunodeficiency or risk of immunosuppression (eg, systemic corticosteroid therapy, chemotherapy, radiation). Thymic dysfunction.
Latex allergy. Have epinephrine (1:1000) available. Elderly (increased risk of systemic events; evaluate prior to, and monitor for at least 10 days after, vaccination). Pregnancy (Cat.C). Nursing mothers.
Concomitant vaccines: see literature.
Yellow fever vaccine.
Injection site reactions, rash, headache, malaise, myalgia, fever; rare neurotropic or viscerotropic disease.
Available only to Yellow Fever Vaccination Centers.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy